[{"from": "human", "value": "Provide a description of this molecule. [C][C][N][C][C][=C][Branch1][N][C][=C][C][=Branch1][=Branch1][=C][Ring1][=Branch1][C][#N][F][O][C@H1][Branch2][Ring1][Branch2][C][N][C][=Branch1][C][=O][C][=C][N][=C][Ring2][Ring1][Branch1][C][=C][N][Ring1][=Branch1][N][=C][Ring1][=Branch2][N][C]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable, multi-targeted kinase inhibitor with potential antineoplastic activity. Upon oral administration, elzovantinib binds to and inhibits three tyrosine kinases that are often overexpressed in a variety of cancer cell types, including MET (c-Met; hepatocyte growth factor receptor; HGFR) , Src, and colony stimulating factor 1 receptor (CSF1R; CSF-1R; C-FMS; CD115; macrophage colony-stimulating factor receptor; M-CSFR) thereby disrupting their respective signaling pathways. MET, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis. Src, a non-receptor tyrosine kinase upregulated in many tumor cell types, plays an important role in tumor cell proliferation, motility, invasiveness and survival. CSF1R is a cell-surface receptor for colony stimulating factor 1 (CSF1); this receptor tyrosine kinase is overexpressed by tumor-associated macrophages (TAMs) in the tumor microenvironment (TME), and plays a major role in both immune suppression and the induction of tumor cell proliferation."}]